Clinical Trial Update: Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy and safety of HCP1105 in combined hyperlipidemia patients at high risk for coronary heart disease; current status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Hyperlipidemia

Drugs mentioned

• HCP1105

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Hyperlipidemias | Phase 3 | Status: UNKNOWN